Zaro-001
Research type
Research Study
Full title
A Phase I Study Evaluating the Effect of Clozapine on B Cell Number and Function in Healthy Volunteers
IRAS ID
250539
Contact name
Alex Leech
Contact email
Sponsor organisation
Zarodex Limited
Eudract number
2018-002527-42
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 3 months, 1 days
Research summary
Clozapine is a medicine that is currently used to treat mental illnesses. Recent research has suggested that Clozapine might reduce parts of the immune system responsible for causing diseases in some people. At the high doses usually used in patients with mental illnesses clozapine can have some side effects but research has suggested that lower doses may be suitable for treating diseases caused by this part of the immune system.
The main purpose of this study is to see if a low dose of clozapine is able to reduce the specific parts of the immune system and so could be used as a new treatment for diseases caused by this part of the the immune system
REC name
South Central - Oxford A Research Ethics Committee
REC reference
18/SC/0294
Date of REC Opinion
19 Oct 2018
REC opinion
Further Information Favourable Opinion